Relafen 750 represents a significant example within the metabolic pharmacy landscape . This mechanism of effect fundamentally targets cyclooxygenase catalysts , specifically COX-1 , reducing the production of prostaglandins . Considering a molecular viewpoint , Relafen's clinical benefit copyrights on its power to largely inhibit tissue damage whil